- Home
- NCPL vs APVO Comparison
NCPL vs APVO Comparison
Compare NCPL & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- APVO
- Stock Information
- Founded
- NCPL 1984
- APVO 2016
- Country
- NCPL United States
- APVO United States
- Employees
- NCPL N/A
- APVO N/A
- Industry
- NCPL Investment Managers
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- APVO Health Care
- Exchange
- NCPL Nasdaq
- APVO Nasdaq
- Market Cap
- NCPL 4.3M
- APVO 4.1M
- IPO Year
- NCPL N/A
- APVO N/A
- Fundamental
- Price
- NCPL $2.67
- APVO $4.72
- Analyst Decision
- NCPL
- APVO Strong Buy
- Analyst Count
- NCPL 0
- APVO 1
- Target Price
- NCPL N/A
- APVO $296.00
- AVG Volume (30 Days)
- NCPL 153.1K
- APVO 376.0K
- Earning Date
- NCPL 07-28-2025
- APVO 05-14-2025
- Dividend Yield
- NCPL N/A
- APVO N/A
- EPS Growth
- NCPL N/A
- APVO N/A
- EPS
- NCPL N/A
- APVO N/A
- Revenue
- NCPL $812,612.00
- APVO N/A
- Revenue This Year
- NCPL N/A
- APVO N/A
- Revenue Next Year
- NCPL $101.16
- APVO N/A
- P/E Ratio
- NCPL N/A
- APVO N/A
- Revenue Growth
- NCPL N/A
- APVO N/A
- 52 Week Low
- NCPL $1.41
- APVO $4.30
- 52 Week High
- NCPL $11.90
- APVO $658.60
- Technical
- Relative Strength Index (RSI)
- NCPL 75.93
- APVO 25.64
- Support Level
- NCPL $1.75
- APVO $4.30
- Resistance Level
- NCPL $2.19
- APVO $5.18
- Average True Range (ATR)
- NCPL 0.18
- APVO 1.21
- MACD
- NCPL 0.04
- APVO 0.73
- Stochastic Oscillator
- NCPL 89.01
- APVO 4.18
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.